Severe pancytopenia from thiopurine methyltransferase deficiency: A preventable complication of 6-mercaptopurine therapy in children with Crohn disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 35, Issue 5, 2002, Pages 695-699

  Rosen, Rachel ^a   Integlia, Mark J ^b   Bousvaros, Athos ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MAINE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLONIDINE; CORTICOSTEROID; FAMOTIDINE; FOLIC ACID; HYDROXYZINE; MERCAPTOPURINE; MESALAZINE; METRONIDAZOLE; PREDNISONE; SALAZOSULFAPYRIDINE; THIOPURINE METHYLTRANSFERASE; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; METHYLTRANSFERASE;

ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CHILD; CLINICAL FEATURE; CROHN DISEASE; DRUG WITHDRAWAL; ENZYME DEFICIENCY; FEMALE; HEMATOCRIT; HUMAN; LEUKOCYTE COUNT; MALE; PANCYTOPENIA; PRIORITY JOURNAL; ADOLESCENT; CHEMICALLY INDUCED DISORDER; GENETICS; GENOTYPE; PRESCHOOL CHILD;

6-MERCAPTOPURINE; ADOLESCENT; AZATHIOPRINE; CHILD, PRESCHOOL; CROHN DISEASE; FEMALE; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHYLTRANSFERASES; PANCYTOPENIA;

EID: 1842832303     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200211000-00021     Document Type: Article

References (21)

1. Present D, Korelitz B, Wisch N, Glass J, Sachar D, Pasternack B. Treatment of Crohn's disease with 6-mercaptopurine. N Engl J Med 1980;302:981-7.
2. Markowitz J, Rosa J, Grancher K, Aiges H, Daum F. Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease. Gastroenterology 1990;99:1347-51.
3. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F, 6 mercaptopurine study group. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895-902.
4. Kader HA, Raynor SC, Young R, et al. Introduction of 6-mercaptopurine in Crohn's disease patients during the perioperative period: A preliminary evaluation of recurrence of disease [see comments]. J Ped Gastroenterol Nutr 1997;25:93-7.
5. Verhave M, Winter H, Grand R. Azathioprine in the treatment of children with inflammatory bowel disease. J Pediatrics 1990;117:809-14.
6. Kader HA, Mascarenhas MR, Piccoli DA, Stouffer NO, Baldassano RN. Experiences with 6-mercaptopurine and azathioprine therapy in pediatric patients with severe ulcerative colitis. J Ped Gastroenterol Nutr 1999;28:54-8.
7. Kirschner BS. Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease. Gastroenterology 1998;115:813-21.
8. Present D, Meltzer S, Krumholz M, Wolke A, Medicine BKAoI. 6-Mercaptopurine in the management of inflammatory bowel disease: Short and long-term toxicity. Annals of Internal Medicine 1989;111:641-49.
9. Connell W, Kamm M, Dickson M, Balkwill A, Ritchie J, Lennard-Jones J. Long-term neoplasia risk after azathioprine treatment in Crohn's disease. Lancet 1994;343:1249-52.
10. Dayharsh GA, Loftus EV Jr. Sandborn WJ. Tremaine WJ. Zinsmeister AR. Witzig TE.Macon WR. Burgart LJ. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002;122:72-77.
11. Cuffari C, Theoret Y, Latour S, Seidman E. 6-Mercaptopurine metabolism in Crohn's disease: Correlation with efficacy and toxicity. Gut 1996;39:401-06.
12. Dubinsky M, Lamothe S, Yang H, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000;118:705-13.
13. Dubinsky M, Lamothe S, Sinnett D, Theoret Y, Seidman E. 6-MP metabolite levels predict clinical efficacy and drug toxicity in pediatric IBD. J Pediatr Gastroenterol Nutr 1998;27:A465.
14. Weinshilboum R, Otterness D, Szumlanski C. Methylation pharmacogenetics: Catechol O-methyltransferase, Thiopurine methyltransferase, and Histamine N-methyltransferase. Annual Reviews Pharmacol Toxicol 1999;39:19-52.
15. McBride K, Gilchrist G, Smithson W, Weinshilboum R, Szumlanski C. Severe 6-thioguanine related marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. J Ped Hematol/Oncol 2000;22:441-45.
16. McLeod H, Krynetski E, Relling M, Evans W. Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia. Leukemia 2000;14:567-72.
17. Colombel J, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000;118:1025-30.
18. Lewis L, Benin A, Szumlanski C, Otterness D, Lennard L. Olsalazine and 6-mercaptopurine related bone marrow suppression: A possible drug-drug interaction. Clin Pharmacol Ther 1997;62:464-75.
19. Lennard L, Lilleyman J, Loon JV, Weinshilboum R. Genetic variation in response to 6-mercaptopurine for childhood acute lymphoblastic leukemia. Lancet 1993;336:225-29.
20. Stolk J, Boerbooms A, deAbreu R, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1858-66.
21. Ishioka S, Hiyama K, Yamanishi Y, et al. Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese. Intern Med 1999;38:944-47.